{"id":4464,"date":"2026-11-18T09:00:00","date_gmt":"2026-11-18T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4464"},"modified":"2026-11-21T09:11:53","modified_gmt":"2026-11-21T13:11:53","slug":"vitrivax-raises-87-million-dollars-for-lyme-vaccine-and-formulation","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4464","title":{"rendered":"VitriVax Raises 87 Million Dollars for Lyme Vaccine and Formulation"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"512\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_VitriVax_Deal_and_Financing-768x512.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4466\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_VitriVax_Deal_and_Financing-768x512.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_VitriVax_Deal_and_Financing-300x200.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_VitriVax_Deal_and_Financing-1024x683.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_VitriVax_Deal_and_Financing.png 1536w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>VitriVax<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Series C financing ($87 million; previously missed 18 Nov event)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Thermostable vaccine formulation (ALTA atomic layering)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Lyme disease vaccine candidate<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Borrelia (antigen undisclosed)<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Lyme disease<\/p>\n<h4>Summary<\/h4>\n<p>VitriVax announced an $87 million Series C on November 18 to advance a Lyme disease vaccine candidate into first-in-human testing and broaden its thermostable vaccine formulation platform. It is new private capital with a defined translational use, but the product remains preclinical.<\/p>\n<p>F-Prime Capital, NEA, RA Capital and Sanofi Ventures co-led the oversubscribed round, with Eli Lilly participating. VitriVax says proceeds will support clinical entry of its Lyme candidate and ALTA atomic-layering technology. The candidate antigen composition, trial protocol and human immunogenicity are not yet disclosed. This November 18 announcement was missed in the earlier daily archive and is included as a 14-day source-gap recovery.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> investors are funding a potentially useful single-dose, temperature-resilient delivery platform with implications for difficult vaccine distribution. Counterpoint: formulation stability and animal immunogenicity may not predict durable human protection against heterogeneous Borrelia strains.<\/p>\n<p><strong>Interpretation B:<\/strong> the financing could mainly buy time to generate first-human data rather than validate the platform. Counterpoint: a large syndicate and specific lead program show committed diligence, though investor participation is not efficacy evidence. Translational tests include antigen integrity, adjuvant release, neutralizing response, strain breadth, reactogenicity, GMP particle consistency and cost per dose.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>VitriVax is a Colorado biotechnology company using ALTA atomic layering to package vaccine antigens and adjuvants for controlled release. Lyme disease is a tick-borne Borrelia infection; the specific antigen and immune mechanism of its candidate were not disclosed in the financing release.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified facts: company financing announcement and named investors.<\/li>\n<li>Company claims: platform performance and development plan.<\/li>\n<li>Missing: valuation, runway, candidate mechanism detail, clinical record and published human data.<\/li>\n<li>Upgrade: registered study with safety and durable strain-broad responses.<\/li>\n<li>Downgrade: loss of potency on storage or repeat-manufacturing variability.<\/li>\n<li>Falsifier: no clinically relevant immune response at feasible dose.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>This is a significant Series C for vaccine delivery and a specific infectious-disease program, but does not yet establish clinical platform value.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 3 of 5. Signal Direction: neutral. Confidence in Facts: High. Confidence in Interpretation: Low to Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>VitriVax announced an $87 million Series C on November 18 to advance a Lyme disease vaccine candidate into first-in-human testing and broaden its thermostable vaccine formulation platform. It is new private capital with a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4466,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[1581,1057,1580],"class_list":["post-4464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-lyme-disease","tag-series-c","tag-vitrivax"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4464"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4464\/revisions"}],"predecessor-version":[{"id":4488,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4464\/revisions\/4488"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4466"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}